SCHEMBL5661900

SCHEMBL5661900

CN(C)CCCNCC(=O)Nc1ccc(Oc2ccccc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.70
LTA4H P09960 8/20 0.70
SMN1; SMN2 Q16637 3/20 0.62
RECQL P46063 1/20 0.61
RNF4 P78317 1/20 0.57
HDAC3 O15379 1/20 0.53
HDAC4 P56524 1/20 0.53
HDAC1 Q13547 1/20 0.53
HDAC7 Q8WUI4 1/20 0.53
HDAC2 Q92769 1/20 0.53
HDAC10 Q969S8 1/20 0.53
HDAC11 Q96DB2 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
HDAC9 Q9UKV0 1/20 0.53
HDAC5 Q9UQL6 1/20 0.53
GAA P10253 1/20 0.52
NPY5R Q15761 1/20 0.52
ALDH1A1 P00352 1/20 0.52
HTT P42858 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5664370 0.96 KDM4E (0.69) KDM4ELTA4HSMN1; SMN2RECQLRNF4
SCHEMBL5661882 0.95 KDM4E (0.67) KDM4ELTA4HSMN1; SMN2RECQLRNF4
SCHEMBL5660273 0.95 KDM4E (0.67) KDM4ELTA4HSMN1; SMN2RECQLRNF4
SCHEMBL5661261 0.92 KDM4E (0.77) KDM4ELTA4HSMN1; SMN2RECQLRNF4
SCHEMBL22069671 0.86 GAA (0.73) KDM4ELTA4HSMN1; SMN2RECQLRNF4
SCHEMBL5661438 0.85 KDM4E (0.70) KDM4ELTA4HSMN1; SMN2RECQLRNF4
SCHEMBL5662163 0.84 KDM4E (0.54) KDM4ELTA4HSMN1; SMN2RECQLRNF4
SCHEMBL5661992 0.84 LTA4H (0.63) KDM4ELTA4HSMN1; SMN2RECQLRNF4
SCHEMBL5661162 0.83 LTA4H (0.73) LTA4HSMN1; SMN2RNF4HDAC3HDAC4
SCHEMBL5659423 0.83 LTA4H (0.65) KDM4ELTA4HSMN1; SMN2RECQLRNF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070155727-A1 Amide inhibitors of leukotriene A4 hydrolase SCHERING AKTIENGESSELLSCHAFT (DE) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155727-A1 Amide inhibitors of leukotriene A4 hydrolase LTA4H, LTB4R, LTC4S KDM4E 1019/4885LTA4H 1/4885SMN1; SMN2 4751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.